Hey FingersBelow is a copy of Biotrons latest update on testing...

Hey Fingers

Below is a copy of Biotrons latest update on testing compounds. I believe compounds work on COVID 19 IMO this great little Aussie Company is just about to save the day. $5 by end of next week. The always optimistic Oaktree dyor

Biotron’s core expertise lies in the design and development of drugs that target virus-encoded proteins known as viroporins. Viroporins are found in a broad range of viruses and play key roles in viral pathogenesis. Viroporins are central to viruses modifying host immune responses so that they can fly under the radar and establish and maintain ongoing cycles of infection. Biotron has designed and developed a library of compounds that target viroporins from a broad range of different viruses that cause serious infections in humans and other hosts.Within Biotron’s anti-viroporin library are compounds that have shown good activity against a range of coronaviruses, based on studies that were undertaken at the time of outbreak of severe acute respiratory syndrome (SARS-1) – which was a coronavirus – back in 2002-2004. The Company’s scientists were the first to identify and publish data showing that the E protein of the coronavirus is a viroporin and a good target for antiviral drugs.In February this year, Biotron began testing a range of its compounds against SARS-CoV-2, the causative agent of COVID-19, to assess whether they can inhibit this new coronavirus. This work is progressing well in a series of different assays are to assess impact of the compounds on markers of virus replication as well as immune markers. These assays will provide the best overall understanding of the potential of Biotron’s compounds to treat COVID-19.Biotron remains focused on progressing its antiviral programs directed at viroporins through to a commercial outcome. The current pandemic highlights the importance of novel approaches such as Biotron’s with its potential to target a broad range of existing and emerging viruses.CommercialisationDevelopment of new drugs is a slow, measured process. The strict international regulatory and safety requirements mean that there are no shortcuts to the development of new drugs. Similarly, beneficial partnerships in the biopharmaceutical industry take time. They are dependent on good science, addressing clear unmet medical needs, and rigorous data.Biotron’s core antiviral programs have all these key elements.